Plain-English translation of NCT06471205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing combined with a in people with triple-negative breast cancer that has advanced or come back after treatment. The study wants to see if this medication combination is effective and safe for patients whose cancer cannot be surgically removed. Researchers will enroll about 52 people to evaluate how well the treatment works.
Triple-negative breast cancer is an aggressive form of the disease that is difficult to treat because standard hormone-based therapies don't work on it. This trial exists to explore whether combining two newer types of immunotherapy medications might offer a new treatment option for patients with advanced disease.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as an intravenous infusion (through an IV) during a treatment cycle lasting 3 weeks. If your cancer responds well and you tolerate the medication, you may continue with additional treatment cycles. Your doctor will monitor you regularly for how well the treatment is working and for any side effects, and treatment will stop if your cancer progresses, you experience serious side effects, or for other medical reasons.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China